When and How to Increase Your GLP-1 Microdose

If you're microdosing a GLP-1 — taking a fraction of the standard semaglutide or tirzepatide dose — the most common question after the first few weeks is: should I go up, and when? This page is an honest guide to the escalation decision, not a prescription. The single most important rule borrowed from how these drugs are actually dosed: don't raise the dose any sooner than every four weeks. But the bigger truth is that microdose titration is off-label and unstudied, so the real decision belongs with a clinician — and the framework below exists to make that conversation sharper, not to replace it.

First, the honesty layer

There is no trial of GLP-1 microdose titration. The four-week cadence, the dose steps, and the "raise it when you plateau" logic are all extrapolated from how full-dose GLP-1 drugs are escalated in their approved schedules and trials — not from any study of microdosing. Microdosing also almost always uses compounded product, because approved pens don't come in microdose strengths, and a pharmacovigilance analysis of compounded GLP-1 agonists found elevated reporting for preparation errors and dosing mistakes ¹. So treat everything here as a structured way to think, anchored to real dosing science, not as validated microdose protocol.

The non-negotiable rule: no sooner than every 4 weeks

This is the one number to internalize. The FDA-approved escalation schedules space dose increases at least four weeks apart. Wegovy's label initiates at 0.25 mg once weekly for four weeks, then titrates every four weeks up to the maintenance dose ². Tirzepatide is escalated on the same four-week rhythm in its trials and label-based dosing. The four-week spacing isn't arbitrary — it gives the gut time to accommodate the drug's slowed gastric emptying, which is what makes nausea, the dominant dose-related side effect, fade before you add more ³. Raising a microdose faster than this throws away the main advantage of going low in the first place: tolerability. Four weeks at a given dose is the floor, not a target to beat.

When increasing is actually justified

The honest trigger for going up is a genuine plateau of the effect you're after, after you've held the current dose long enough to judge it. In practice that means:

• •Food noise and appetite have returned. If the appetite-quieting effect that the dose initially produced has clearly worn off and stayed gone, that's the most defensible signal — appetite reduction is a core, dose-dependent GLP-1 effect ⁴.
• •Weight loss has stalled for several weeks at a dose you've tolerated well. Because effect scales with dose — a phase 2 dose-ranging trial showed weight loss climbing from about −6% at the lowest dose to −13.8% at higher doses ⁴ — a true plateau at a low dose is the situation where a step up is most likely to do something. But give it time: a few flat days is not a plateau.
• •Side effects at the current dose are mild or gone. You should only consider adding dose from a position of good tolerance, never to "push through" active nausea or GI distress.

What is not a good reason: impatience, a number on the scale you wanted by an arbitrary date, or the assumption that more is automatically better. A normal weight-loss curve flattens and resumes; chasing every flat week with a dose increase is how people end up at full-dose side effects without intending to.

How to step up (and the ceiling question)

If escalation is justified, the conservative approach mirrors the approved schedules: move up by one modest increment, then hold at the new dose for at least four weeks before judging it again. Resist doubling. Each step up moves you along the dose-response curve toward larger effects — but also toward the dose-related side effects you were trying to avoid, since GI adverse events are the most common reason people struggle with these drugs ³. There's also a natural ceiling: once you're escalating into standard therapeutic ranges, you are no longer "microdosing" — you're simply on a GLP-1, and the honest move is to be on a properly prescribed, approved product rather than a compounded approximation. We compare the two worlds in low-dose vs full-dose GLP-1.

Don't forget what a higher dose costs

Going up isn't free of trade-offs beyond side effects. GLP-1 weight loss includes muscle loss — a meta-analysis found GLP-1 receptor agonists reduce muscle mass alongside fat ⁵ — and faster, larger loss from a higher dose can mean more lean-mass loss if protein intake and resistance training aren't deliberate. And the benefit tracks ongoing exposure: in STEP 4, continued semaglutide maintained weight loss while switching to placebo led to regain ⁶, and the STEP 1 extension showed roughly two-thirds of lost weight returning after withdrawal ⁷. Escalating to chase a number you can't sustain sets up the same regain dynamic at a higher dose. For the day-to-day side-effect picture, see microdose GLP-1 side effects and the dose math in GLP-1 dose-response.

The honest bottom line

The mechanics are simple: hold each dose at least four weeks, raise it only for a real, sustained plateau when you're tolerating the current dose well, step up by one modest increment, and never escalate to push through active side effects. The framing is the important part: GLP-1 microdose titration is off-label, unstudied, and usually done with compounded product, so this is a decision to make with a prescriber who can monitor you — not a self-directed protocol. If you find yourself escalating into standard therapeutic doses, that's the signal to step onto a properly prescribed, approved GLP-1 instead.

To sketch a step-by-step ramp to take into that clinician conversation, our microdose titration planner lays out a week-by-week schedule from your inputs — a planning aid, not a protocol.

Titration is the back half of the practice — for the whole sequence from sourcing through injection, see how to microdose GLP-1: the honest step-by-step. For related reading, see the microdosing tirzepatide dose chart, the GLP-1 microdosing chart, microdosing for weight-loss maintenance, microdosing GLP-1: what the evidence shows, and our GLP-1 microdose rankings hub.